Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Unit price / market price
-
$2.19
-
Total 13F principal
-
$229,681,000
-
Principal change
-
-$13,626,000
-
Total reported value
-
$503,037,000
-
Number of holders
-
17
-
Value change
-
-$8,237,722
-
Number of buys
-
9
-
Number of sells
-
11
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q1 2018
As of 31 Mar 2018 LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 had 17 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $229,681,000 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included CITADEL ADVISORS LLC, Polygon Management Ltd., WOLVERINE ASSET MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, CALAMOS ADVISORS LLC, ANGELO GORDON & CO., L.P., Allianz Asset Management GmbH, CSS LLC/IL, PIPER JAFFRAY & CO., and GOLDMAN SACHS GROUP INC.
This table shows 17 bond principal holders of the security as of 31 Mar 2018.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.